Table 1.

Rates of most commonly reported adverse events during dasatinib studies

Variable	Chronic stage		Accelerated phase	MBC	LBC	Ph+ALL
Regimen and Dose	100 mg qd	70 mg bid	70 mg bid
n	165	655	174	109	48	46
Study	CA-180-034	CA-180-034 and START-C	START-A	START-B	START - L	START - L
G3/4 Cytopenia (%)
Neutropenia	34	43 - 61	76	80	81	78
Thrombocytopenia	22	38 - 56	82	82	88	78
Leukopenia	17	23 - 27	59	61	71	65
Anemia	10	17 - 21	69	69	50	NR
Fever (%)
All Grades	4	10 - 14	24	20	17	22
G3/4	< 1	0 - 1	4	5	2	2
Pleural Effusion (%)
All Grades	10	17- 27	27	36	13	24
G3/4	2	2 - 6	5	15	6	7
Peripheral Edema (%)
All Grades	10	10 - 18	22	18	13	13
G3/4	0	0	< 1	0	0	0
Dyspnea (%)
All Grades	13	14 - 30	21	21	13	NR
G3/4	2	4 - 5	4	6	2	NR
Diarrhea (%)
All Grades	23	25 - 37	52	39	33	33
G3/4	< 1	2 - 4	8	7	2	9
Nausea (%)
All Grades	18	24 - 27	28	19	25	22
G3/4	< 1	0 - 1	< 1	4	0	0
Vomiting (%)
All Grades	7	9 - 11	20	22	25	11
G3/4	< 1	0 - 1	2	3	2	0
Headache (%)
All Grades	32	25 - 32	29	10	17	NR
G3/4	< 1	1 - 2	< 1	2	2	NR
Fatigue (%)
All Grades	21	17-31	26	18	27	NR
G3/4	2	2 - 4	4	2	4	NR
Skin Rash (%)
All Grades	13	16 - 26	21	14	17	15
G3/4	1	0 - 1	1	0	4	2

MBC = myeloid blast crisis; LBC = lymphoid blast crisis; ALL = acute lymphoblastic Leukemia; n = number of patients; NR = not reported